Sotorasib Tablets Global Market Report 2026

Sotorasib tablets are a prescription medication designed for the treatment of specific cases of non-small cell lung cancer in patients whose tumors have the KRAS G12C gene mutation. The drug works by attaching to the abnormal KRAS protein, blocking it from sending signals that promote the uncontrolled growth and survival of cancer cells. This targeted inhibition can decrease tumor activity, slow disease progression, and enhance treatment outcomes in patients with limited options using standard therapies.

The primary dosage forms of sotorasib tablets include 40 milligrams (mg), 120 milligrams (mg), 240 milligrams (mg), and other strengths. The 40 mg tablets provide a lower-strength option of the KRAS G12C inhibitor Lumakras, allowing precise dose adjustments to enhance safety and tolerability. Sotorasib is administered to patient populations such as adolescents, adults, and senior adults. It is supplied through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other distribution networks, and is applied for conditions including non-small cell lung cancer, colorectal cancer, and other indications. The end-users consist of hospitals, oncology centers, clinics, and other healthcare providers.

Tariffs are impacting the sotorasib tablets market by increasing costs of imported active ingredients, formulation materials, clinical trial supplies, and specialized manufacturing inputs. North America and Europe are most affected due to reliance on globally sourced pharmaceutical components, while Asia-Pacific experiences export-related cost pressures. These tariffs are influencing drug pricing and market access strategies. However, they are also encouraging local production partnerships, domestic API manufacturing, and greater investment in regional pharmaceutical supply chains to improve long-term availability.

The sotorasib tablets market research report is one of a series of new reports from The Business Research Company that provides sotorasib tablets market statistics, including sotorasib tablets industry global market size, regional shares, competitors with a sotorasib tablets market share, detailed sotorasib tablets market segments, market trends and opportunities, and any further data you may need to thrive in the sotorasib tablets industry. This sotorasib tablets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sotorasib tablets market size has grown rapidly in recent years. It will grow from $1.92 billion in 2025 to $2.16 billion in 2026 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to increasing diagnosis of non-small cell lung cancer, advancements in kras mutation research, regulatory approvals for targeted oncology drugs, expansion of molecular diagnostic capabilities, growth in oncology clinical trials.

The sotorasib tablets market size is expected to see rapid growth in the next few years. It will grow to $3.4 billion in 2030 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to increasing development of next-generation kras inhibitors, rising combination therapy approaches, expansion of targeted treatments into additional cancer indications, growing use of real-world evidence studies, increasing oncology precision medicine adoption. Major trends in the forecast period include increasing adoption of kras g12c inhibitor therapies, rising focus on targeted lung cancer treatments, growing use of oral oncology medications, expansion of companion diagnostic testing, enhanced monitoring of resistance mechanisms.

The increasing prevalence of cancer is expected to drive the growth of the sotorasib tablets market in the coming years. Cancer is a collection of diseases characterized by abnormal cells that grow uncontrollably, invade surrounding tissues, and can spread to other parts of the body. The rise in cancer cases is attributed to the aging population, as older age is the most significant risk factor for developing most types of cancer, with the majority of cases occurring in individuals over 65 years old. Sotorasib tablets act by selectively and irreversibly targeting the KRAS G12C mutation, locking the mutated protein in an inactive state to prevent uncontrolled cell growth in patients with advanced solid tumors, particularly non-small cell lung cancer. For example, in February 2024, the World Health Organization, a Switzerland-based international organization focused on global health policy and public health initiatives, projected over 35 million new cancer cases in 2050, representing a 77% increase from the estimated 20 million cases in 2022. Consequently, the rising prevalence of cancer is fueling the growth of the sotorasib tablets market.

The increasing geriatric population is expected to drive the growth of the sotorasib tablets market going forward. The geriatric population refers to older adults, generally aged 65 years and above, who may experience physiological, psychological, and social changes associated with aging. The rise in the geriatric population is mainly attributed to longer life expectancy, as improvements in healthcare, nutrition, and living conditions enable more people to live longer, resulting in a higher proportion of older adults within the population. Sotorasib tablets benefit the geriatric population by targeting KRAS G12C-mutated cancers, providing a precision therapy that addresses age-related vulnerabilities and enhances treatment outcomes in older adults. For example, in July 2024, according to the UK Parliament's House of Commons Library, a UK-based government administration, there were 12.7 million people aged 65 or older in the UK in 2022, representing 19% of the total population. This number is projected to increase to 22.1 million by 2072, accounting for 27% of the population. Consequently, the growing geriatric population is fueling the expansion of the sotorasib tablets market.

Major companies operating in the sotorasib tablets market are concentrating on developing innovative therapies such as combination treatments to enhance efficacy and address resistance. Combination treatments involve using two or more drugs together to target cancer through multiple mechanisms simultaneously, helping to improve treatment effectiveness, overcome or delay drug resistance, reduce the risk of cancer recurrence, and enhance overall patient outcomes and quality of life. For example, in January 2025, Amgen Inc., a US-based biotechnology company, received U.S. Food and Drug Administration (FDA) approval for sotorasib in combination with panitumumab for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) who had previously undergone standard chemotherapy. This approval was supported by the results of the Phase 3 CodeBreaK 300 study, which showed that the combination more than doubled progression-free survival compared to the investigator's choice of standard-of-care therapy, offering a significant new option for patients with this hard-to-treat cancer. Sotorasib is a first-in-class, oral KRAS G12C inhibitor that works by selectively targeting and locking the mutant KRAS protein in its inactive state, thereby inhibiting cancer cell growth and signaling pathways driven by this mutation.

Major companies operating in the sotorasib tablets market are Amgen Inc.

North America was the largest region in the sotorasib tablets market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotorasib tablets market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the sotorasib tablets market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sotorasib tablets market consists of sales of lumakras, lumykras, and diagnostic companion kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sotorasib Tablets Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses sotorasib tablets market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for sotorasib tablets ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The sotorasib tablets market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Dosage Form: 40 Milligrams (Mg) Tablets; 120 Milligrams (Mg) Tablets; 240 Milligrams (Mg) Tablets; Other Dosage Forms
• 2) By Patient Demographics: Adolescents; Adult; Senior Adults
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• 4) By Application: Non-Small Cell Lung Cancer; Colorectal Cancer; Other Applications
• 5) By End-User: Hospitals; Oncology Centers; Clinics; Other End-Users
• Companies Mentioned: Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.